| Jessica Rose Berlasi, CRNA | |
|
44201 Dequindre Rd, Troy, MI 48085-1117 | |
| (248) 964-3000 | |
| (248) 964-8448 |
| Full Name | Jessica Rose Berlasi |
|---|---|
| Gender | Female |
| Speciality | Certified Registered Nurse Anesthetist (crna) |
| Experience | 8 Years |
| Location | 44201 Dequindre Rd, Troy, Michigan |
| Accepts Medicare Assignments | May be. She may accept the Medicare-approved amount; you may be billed for more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1215472469 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367500000X | Nurse Anesthetist, Certified Registered | 4704289994 (Michigan) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Beaumont Hospital, Troy | Troy, MI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Northstar Anesthesia Of Michigan Iii Pllc | 7911325469 | 526 |
News Archive
Aerocrine AB announces that a nine-member council representing both prestigious asthma societies, the American Academy and the American College of Allergy, Asthma and Immunology (ACAAI and AAAAI), have published a position statement in support of the clinical practice guideline on Aerocrine's FeNO test as published by the ATS.
Each year about 3300 Australian men die of prostate cancer. It's Australia's second worst cancer killer for men, matching the impact of breast cancer on women. Current therapies for prostate cancer include surgical removal of the prostate, radiation, freezing the tumour or cutting off the supply of the hormone testosterone-but there are often side-effects including incontinence and impotence.
Immunotherapy is one of the latest and most effective armaments against various types of cancers. Some of the immunotherapy drugs such as PD-1 inhibitor Keytruda from Merck can block certain proteins in the cancer cells that can make the cells invisible to the immune system normally. Some of the cancers cells can now develop other ways to disguise themselves from being killed by the immune system.
Ivera Medical Corporation announced today that the United States Patent & Trademark Office (USPTO) will issue a new continuation patent for its innovative Curos disinfecting port protector technology on June 26, 2012. U.S. Patent No. 8,206,514 will cover key aspects of disinfecting caps designed to be used with luer-activated IV valves to disinfect and clean the IV port.
There are times when emergency physicians can't be 100 percent sure a person is suffering from a severe allergic reaction, known as anaphylaxis, and may hesitate to use epinephrine. A new article says when in doubt - administer the epinephrine.
› Verified 2 days ago
| Entity Name | William Beaumont Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1811044878 PECOS PAC ID: 9335051093 Enrollment ID: O20040312000217 |
News Archive
Aerocrine AB announces that a nine-member council representing both prestigious asthma societies, the American Academy and the American College of Allergy, Asthma and Immunology (ACAAI and AAAAI), have published a position statement in support of the clinical practice guideline on Aerocrine's FeNO test as published by the ATS.
Each year about 3300 Australian men die of prostate cancer. It's Australia's second worst cancer killer for men, matching the impact of breast cancer on women. Current therapies for prostate cancer include surgical removal of the prostate, radiation, freezing the tumour or cutting off the supply of the hormone testosterone-but there are often side-effects including incontinence and impotence.
Immunotherapy is one of the latest and most effective armaments against various types of cancers. Some of the immunotherapy drugs such as PD-1 inhibitor Keytruda from Merck can block certain proteins in the cancer cells that can make the cells invisible to the immune system normally. Some of the cancers cells can now develop other ways to disguise themselves from being killed by the immune system.
Ivera Medical Corporation announced today that the United States Patent & Trademark Office (USPTO) will issue a new continuation patent for its innovative Curos disinfecting port protector technology on June 26, 2012. U.S. Patent No. 8,206,514 will cover key aspects of disinfecting caps designed to be used with luer-activated IV valves to disinfect and clean the IV port.
There are times when emergency physicians can't be 100 percent sure a person is suffering from a severe allergic reaction, known as anaphylaxis, and may hesitate to use epinephrine. A new article says when in doubt - administer the epinephrine.
› Verified 2 days ago
| Entity Name | Northstar Anesthesia Of Michigan Iii Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1972126209 PECOS PAC ID: 7911325469 Enrollment ID: O20200915001990 |
News Archive
Aerocrine AB announces that a nine-member council representing both prestigious asthma societies, the American Academy and the American College of Allergy, Asthma and Immunology (ACAAI and AAAAI), have published a position statement in support of the clinical practice guideline on Aerocrine's FeNO test as published by the ATS.
Each year about 3300 Australian men die of prostate cancer. It's Australia's second worst cancer killer for men, matching the impact of breast cancer on women. Current therapies for prostate cancer include surgical removal of the prostate, radiation, freezing the tumour or cutting off the supply of the hormone testosterone-but there are often side-effects including incontinence and impotence.
Immunotherapy is one of the latest and most effective armaments against various types of cancers. Some of the immunotherapy drugs such as PD-1 inhibitor Keytruda from Merck can block certain proteins in the cancer cells that can make the cells invisible to the immune system normally. Some of the cancers cells can now develop other ways to disguise themselves from being killed by the immune system.
Ivera Medical Corporation announced today that the United States Patent & Trademark Office (USPTO) will issue a new continuation patent for its innovative Curos disinfecting port protector technology on June 26, 2012. U.S. Patent No. 8,206,514 will cover key aspects of disinfecting caps designed to be used with luer-activated IV valves to disinfect and clean the IV port.
There are times when emergency physicians can't be 100 percent sure a person is suffering from a severe allergic reaction, known as anaphylaxis, and may hesitate to use epinephrine. A new article says when in doubt - administer the epinephrine.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jessica Rose Berlasi, CRNA 130 Town Center Dr, Troy, MI 48084-1744 Ph: (248) 585-8221 | Jessica Rose Berlasi, CRNA 44201 Dequindre Rd, Troy, MI 48085-1117 Ph: (248) 964-3000 |
News Archive
Aerocrine AB announces that a nine-member council representing both prestigious asthma societies, the American Academy and the American College of Allergy, Asthma and Immunology (ACAAI and AAAAI), have published a position statement in support of the clinical practice guideline on Aerocrine's FeNO test as published by the ATS.
Each year about 3300 Australian men die of prostate cancer. It's Australia's second worst cancer killer for men, matching the impact of breast cancer on women. Current therapies for prostate cancer include surgical removal of the prostate, radiation, freezing the tumour or cutting off the supply of the hormone testosterone-but there are often side-effects including incontinence and impotence.
Immunotherapy is one of the latest and most effective armaments against various types of cancers. Some of the immunotherapy drugs such as PD-1 inhibitor Keytruda from Merck can block certain proteins in the cancer cells that can make the cells invisible to the immune system normally. Some of the cancers cells can now develop other ways to disguise themselves from being killed by the immune system.
Ivera Medical Corporation announced today that the United States Patent & Trademark Office (USPTO) will issue a new continuation patent for its innovative Curos disinfecting port protector technology on June 26, 2012. U.S. Patent No. 8,206,514 will cover key aspects of disinfecting caps designed to be used with luer-activated IV valves to disinfect and clean the IV port.
There are times when emergency physicians can't be 100 percent sure a person is suffering from a severe allergic reaction, known as anaphylaxis, and may hesitate to use epinephrine. A new article says when in doubt - administer the epinephrine.
› Verified 2 days ago
Darlene B Marsich-douglas, CRNA Nurse Anesthetist - CR Medicare: Medicare Enrolled Practice Location: 4550 Investment Dr, Suite 100, Troy, MI 48098 Phone: 248-265-4600 | |
Evelyn Flynn, CRNA Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 44201 Dequindre, 400 Fsc - Pcs, Troy, MI 48085 Phone: 248-423-3144 | |
Karl Thulin, CRNA Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 44201 Dequindre Rd, Anesthesia, Troy, MI 48085 Phone: 248-577-3521 | |
Denise Zeleny, CRNA Nurse Anesthetist - CR Medicare: May Accept Medicare Assignments Practice Location: 44201 Dequindre, 400 Fsc - Pcs, Troy, MI 48085 Phone: 248-423-3144 | |
Andrea M Brown, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 3455 Livernois Rd, Troy, MI 48083 Phone: 248-619-2020 | |
Kelly Carie, CRNA Nurse Anesthetist - CR Medicare: May Accept Medicare Assignments Practice Location: 44201 Dequindre, 400 Fsc - Pcs, Troy, MI 48085 Phone: 248-423-3144 | |
Anna Marie Glaros, CRNA Nurse Anesthetist - CR Medicare: May Accept Medicare Assignments Practice Location: 44201 Dequindre Rd, Troy, MI 48085 Phone: 248-964-3000 Fax: 248-964-8448 |